Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients

International Journal of Urology

Volumn 17, Issue 9, 2010, Pages 811-815

  Ueda, Takeshi ^a   Imamura, Yusuke ^b   Komaru, Atsushi ^a   Fukasawa, Satoshi ^a   Sazuka, Tomokazu ^a   Suyama, Takahito ^b   Naya, Yukio ^b   Nihei, Naoki ^b   Ichikawa, Tomohiko ^b   Maruoka, Masayuki ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

adverse events; metastasis; renal cell carcinoma; sorafenib

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; EVEROLIMUS; INTERLEUKIN 2; SORAFENIB; SUNITINIB;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; JAPANESE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956048116     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02604.x     Document Type: Article

References (16)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 2005 353 : 2477 2490.
2. Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 2010 57 : 317 325.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 1996 335 : 865 875.
4. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006 24 : 2505 2512.
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 125 134. Erratum in: N. Engl. J. Med. 2007; 357: 203.
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009 27 : 3312 3318.
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999 17 : 2530 2540.
8. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000 92 : 205 216.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958 53 : 457 481.
10. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 115 124.
11. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J. Clin. Oncol. 2007 37 : 755 762.
12. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 2007 99 : 81 3.
13. Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007 17 : 351 355.
14. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 2006 145 : 660 664.
15. Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol. 2008 19 : 265 268.
16. Miyake H, Kurahashi T, Yamanaka K et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol. Oncol. 2010 PMID:19914105 (in press).